

# Liver dynamics of HCV infection amongst patients aged 50 years or older visiting a larger tertiary care centre of Hyderabad, Pakistan

## Abstract

**Introduction:** Usually chronic infection of hepatitis C virus (HCV) is asymptomatic until present as acute hepatitis, acute liver failure or development of cirrhosis with decompensation. New era of Direct-acting antiviral (DAAs) for HCV has evolved the treatment with good result and tolerability. Early diagnosis and treatment can halt the further disease progression.

**Methodology:** In this cross sectional study, all the patients with HCV positive either acute or chronic hepatitis infection, cirrhosis with or without decompensation, aged 50 year or above, of either gender, presenting in the outpatient department (OPD) were included.

**Results:** A total of 281 patients were enrolled during the study period. Mean age of the study population was  $56.91 \pm 7.21$  years (range: 50–90 years) and majority were male (51.6%) and with Child class A 136 (48.4%) followed by child class B 96 (34.2%). Majority of patients presented as decompensated cirrhosis and raised transamines 160 (56.9%). Most common complication was variceal bleed 95 (33.8%) followed by ascities 88 (31.3%), pedal edema 24 (8.5%). More than half of the patients were not eligible for treatment. Correlation between age and gender with liver stage and comorbidities was statically significant ( $p=0.001$ ).

**Conclusion:** Late diagnosis present with complication with least options of treatment. Chronic hepatitis C is curable disease and should be diagnosed as early as possible. There should be screening at younger age.

**Keywords:** hepatitis C virus, world health organization, hypertension, haematemesis

Volume 12 Issue 3 - 2021

Jawaid Iqbal, Abdul Hafeez Soomaro, Adil Hassan, Muhammad Mashooque, Bushra Qadir, Sidra Dars, Muhammad Sadik Memon  
Department of Gastroenterology, Asian Institute of Medical Science, Pakistan

**Correspondence:** Jawaid Iqbal, Department of Gastroenterology, Asian Institute of Medical and Science, Hyderabad Pakistan, Tel +923332918511, Email drjaved1982@yahoo.com

**Received:** November 15, 2019 | **Published:** May 03, 2021

**Abbreviations:** HCV, hepatitis C virus; DAAs, Direct-acting antiviral agents; WHO, world health organization; OPD, outpatient department

## Introduction

Chronic infection of hepatitis C virus (HCV) is usually asymptomatic until it present as acute hepatitis, acute liver failure or development of cirrhosis with decompensation. The New era of Direct-acting antiviral agents (DAAs) for HCV has evolved the treatment with good result and tolerability. With the use of direct antiviral agents (DAAs) for chronic HCV infection our knowledge on the pathogenesis, clinical course and the treatment of HCV has increased.

In elderly patients chronic infection may be more severe and is said to be more prevalent.<sup>1</sup> Early diagnosis and treatment can halt the further disease progression, damage of liver disease and death. Late diagnosis effects the treatment efficacy, cost and risk of continuous liver damage. Over 71 million people are affected globally with chronic HCV infection.<sup>2</sup> This has enormous burden on the economy and health sector of any country. The World health organization (WHO) has set the goal to eliminate HCV infection from the world by the year 2030.<sup>3,4</sup>

HCV is endemic in Pakistan and according to a national survey which was conducted in 2007-2008 and the prevalence of HCV is 4.8%.<sup>5</sup> Genotype 3a is most prevalent HCV variant in Pakistan.<sup>6,7</sup> Aim of our study is to determine the behavior of liver who diagnosed late with HCV infection.

## Patients and methods

All consecutive patients with HCV positive either acute or chronic hepatitis or infection, cirrhosis with or without decompensation, aged 50 year or above, of either gender, presenting in the outpatient department (OPD) of Asian Institute of Medical and Science were included. Cirrhosis is a chronic degenerative disease in which normal liver cells are damaged and are then replaced by scar tissue.<sup>8</sup> Decompensated cirrhosis was defined on radiological findings, history of haematemesis and/or clinical evidence of encephalopathy. Patients with less than fifty years of age were excluded from the study. After taking informed consent, blood sample for complete blood count, liver function tests, serum albumin, INR, viral serology and serum creatinine was collected.

## Results

A total of 281 patients were enrolled during the study period. The Mean age of the study population was  $56.91 \pm 7.21$  years (range: 50–90 years) and majority were male (51.6%) and having Child class A 136 (48.4%) followed by child class B 96 (34.2%) (Figure 1). Clinical characteristics and laboratory parameters of the study population are shown in Table 1. Majority of patients were from urban areas at district level 161 (57.3%) with Sindhi ethnicity 176 (62.6%) with poor education under primary 146 (52.0%). More than half of the patients 129 (45.9%) were not eligible for antiviral treatment for chronic HCV. In this population major comorbidities were dyspepsia 205 (73.0%), hypertension 93 (33.1%), diabetes mellitus 68 (24.2%), chronic HBV 57 (20.3%) and Ischemic heart

disease 21(7.5%). Most common complication was variceal bleed 95(33.8%) followed by ascities 88(31.3%), pedal edema with portal hypertension and hepatocellular carcinoma HCC 19(6.8%). Most of the patients presented with common symptoms 79(28.1%) followed by routine screening 71(25.3%). Majority of patients presented as

decompensated cirrhosis and raised transaminases 160 (56.9%) as shown Table 2. Table 3 shows correlation between age and gender with liver stage and comorbids which shows significant correlation of male gender with comorbids and liver stage at the time of diagnosis.




Figure 1 Child-Pugh Classification.

Table 1 Baseline characteristics, comorbid and complications

Variables	Mean ±SD / n (n%)
Age (years)	56.91 ±7.21
Gender	Male 136 (48.4)
	Female 145 (51.6)
Residence	village 34 (12.1)
	Tehsil 36 (12.8)
	District 161 (57.3)
	Division 50 (17.8)
Education	Uneducated 1 (0.4)
	Under Primary 146 (52.0)
	Primary 77 (27.4)
	Matric 32 (11.4)
	FA 2 (0.7)
Ethnicity	graduate 23 (8.2)
	Sindhi 176 (62.6)
	Punjabi 23 (8.2)
	Urdu 61 (21.7)
	Pathan 17 (6.0)
	Baloch 3 (1.1)
Other 1 (0.4)	

Table Continued...

Variables	Mean $\pm$ SD / n (n%)
Eligible for antiviral treatment	129 (45.9)
Comorbid conditions	
Dyspepsia	205 (73.0)
Hypertension	93 (33.1)
Diabetes	68 (24.2)
Hep B	57 (20.3)
Ischemic heart disease	21 (7.5)
Common complications	
Variceal Bleeding	95 (33.8)
Ascites /SBP	88 (31.3)
PSE	40 (14.2)
Only P.Edema +P,HTN	24 (8.5)
HCC	19 (6.8)
Liver failure	6 (2.1)
Others	5 (1.8)
Acute on CHC	4 (1.4)

Age presented in mean standard deviation, categorical data presented in n(n%)

Table 2 Different medium of CHC diagnosis, stages of the liver disease

How do you know about CHC?	n(n%)
Due to symptoms related CHC (fatigue, weakness, fever, etc.)	79(28.1)
Routine screening	71(25.3)
Due to complication	67(23.8)
Due to symptoms of dyspepsia	32(11.4)
Pre-operative screening	17(6.0)
screening U/s abdomen	8(2.8)
Pre transfusion	4(1.4)
Other family members were found to have HBV/HCV	2(.7)
Pre-vaccination screening	1(.4)
<b>Stages of liver disease</b>	
<b>CHC without cirrhosis</b>	105(37.4)
CHC-with normal ALT	29(10.3)
CHC-increased ALT	76(27.0)
<b>CHC with cirrhosis</b>	160(56.9)
CHC-Normal ALT & cirrhosis(compensated)	17(6.0)
CHC-increased ALT & cirrhosis(compensated)	43(15.3)
CHC-Normal ALT & decompensated cirrhosis	20(7.1)
CHC-increased ALT & decompensated cirrhosis	80(28.5)
<b>Others</b>	16(5.7)
CHC-HCC	10(3.6)
CHC-acute or chronic Hepatitis "C"(altered mention)	2(.7)
CHC- acute or chronic Hepatitis "C"(normal mention)	1(.4)

**Table 3** Association between Age groups and Gender with Liver Stage and Comorbids

	Age group		P-Value	Gender		P-Value
	≤ 55 years	>55 years		Male	Female	
<b>Liver Stage</b>	<b>CHC without cirrhosis</b>	62(37.3%)	43(37.4%)		40(29.4%)	65(44.8%)
	<b>CHC with cirrhosis</b>	95(57.2%)	65(56.5%)	0.970	82(60.3%)	78(53.8%)
	<b>Others</b>	9(5.4%)	7(6.1%)		14(10.3%)	2(1.4%)
<b>Comorbids</b>	<b>Diabetes</b>	45(27.1%)	23(20.0%)	0.170	35(25.7%)	33(22.8%)
	<b>Dyspepsia</b>	124(74.7%)	81(70.4%)	0.430	83(61.0%)	122(84.1%)
	<b>HTN</b>	57(34.3%)	36(31.3%)	0.730	33(24.3%)	60(41.4%)

### Statistical analysis

Statistical analysis was performed by SPSS (version 20.0). Mean and standard deviation were calculated for continuous variables, while frequencies and percentages were calculated for categorical variables. Spearman’s correlation coefficient was calculated to document the strength of association between age, gender with liver stage and comorbids.  $P < 0.05$  was considered significant for association between gender with liver stage and comorbids in statistical analysis.

### Discussion

Chronic hepatitis C is common hepatic infection worldwide and very endemic 4.8% in Pakistan.<sup>5</sup> HCV infection in childhood or younger age has high rate of HCV clearance than older age infected patients.<sup>9</sup> Late diagnoses of HCV infection may result inflammation of hepatocytes followed by distortion of architecture and formation of regenerative nodules with end result cirrhosis of liver.<sup>10</sup> The finding from this study suggest that behavior of liver on the basis of liver biomarkers, sonographic appearance and clinically may deteriorate with late diagnosis.

In this group majority of patients were female 145(51.6%) with low education under primary 146(52.0%). More than fifty percent of patients were not eligible for treatment at the time of diagnosis because of the complication and advance age. Male gender is strongly associated with liver stage and comorbids like dyspepsia.

Majority of our patients presented with cirrhosis 160(56.9%) out of them 80 (28.5%) were decompensated with raised ALT at the time of diagnosis while Seeff et al. and Watson et al. has reported that HCV infection with young adult presented without cirrhosis while older age with cirrhosis and advanced age presented with HCC.<sup>9,11</sup> Majority of patients were investigated for constitutional symptoms like fatigue, weakness followed by routine screening and complication. Hassoun et al.<sup>12</sup> also reported that patient with HCV infection age above 50 presented with fatigue.<sup>12</sup>

In our study liver stage is categorized in two groups, chronic hepatitis C with cirrhosis and without cirrhosis. Majority of our patients (43.8%) were cirrhotic with raised ALT and (27%) without cirrhosis with raised ALT in both groups as shown in Table 2. In our study population statically significant association was found between liver stage and comorbids like dyspepsia and hypertension based on gender but no significant association was found with age group after 50years as shown in Table 3. Toyoda et al.<sup>13</sup> also addressed no significant association between age and severity of liver disease. Another study was conducted by Amina et al.<sup>14</sup> which show no association between severity of liver disease based on age group and gender but in our study there is significant association ( $P=0.001$ ) between liver stage and comorbids based on gender.

There are certain limitations in the study. These include its single center origin and small sample size. We also did not perform longitudinal follow-up of this cohort of patients and all the patients were at or above 50 years of age. Despite the above limitations, this study provides a basis for performing multicenter prospective study on a large number of patients.

### Conclusion

Chronic hepatitis C is curable disease and should be diagnosed as early as possible before the development of complication. There should be screening for everyone as early as possible in the countries with intermediate to high prevalence of HCV infection.<sup>15</sup>

### Acknowledgments

None.

### Conflicts of interest

The authors declare that there are no conflicts of interest.

### Funding

None.

### References

1. High KP, Marcus EL, Tur-Kaspa R. Chronic hepatitis C virus infection in older adults. *Clinical Infectious Diseases*. 2005;41(11):1606–1612.
2. Spearman CW, Afihene M, Ally R, et al. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. *Lancet Gastroenterol Hepatol*. 2017;2(12):900–909.
3. World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva: World Health Organization; 2016.
4. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016.
5. Qureshi H, Bile KM, Jooma R, et al. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. *East Mediterr Health J*. 2010;16 Suppl:S15–S23.
6. Hamid S, Umar M, Alam A, et al. PSG consensus statement on management of hepatitis C virus infection—2003. *J Pak Med Assoc*. 2004;54(3):146.
7. Waheed Y, Shafi T, Safi SZ, et al. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. *World Journal of Gastroenterology: WJG*. 2009;15(45):5647.
8. Xu R, Zhang Z, Wang FS. Liver fibrosis: mechanisms of immune-mediated liver injury. *Cell Mol Immunol*. 2012;9(4):296–301.

9. Seeff LB. Natural history of chronic hepatitis C. *Hepatology*. 2002;36(5B):S35–S46.
10. Schuppan D, Afdhal NH. Liver cirrhosis. *The Lancet*. 2008;371(9615):838–851.
11. Watson JP, Brind AM, Chapman CE, et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. *Gut*. 1996;38(2):269–276.
12. Hassoun Z, Willems B, Deslauriers J, et al. Assessment of fatigue in patients with chronic hepatitis C using the fatigue impact scale. *Dig Dis Sci*. 2002;47(12):2674–2681.
13. Toyoda H, Kumada T, Kiriya S, et al. Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C. *Dig Dis Sci*. 2004;49(2):295–299.
14. Nadeem A, Hussain MM, Aslam M. Correlation of serum alanine aminotransferase and aspartate aminotransferase levels to liver histology in chronic hepatitis C. *J Coll Physicians Surg Pak*. 2010;20(10):657–651.
15. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology*. 2015;62(3):932–954.